Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor

By Yokono Masanori  

Endocrine Research, Vol. 38, Iss. 3, 2013-08 ,pp. : 168-183

Informa Healthcare

Access to resources Recommend Favorite

IN VITRO EFFECTS OF INOGATRAN, A SELECTIVE LOW MOLECULAR WEIGHT THROMBIN INHIBITOR

By Teger-Nilsson A.-C.   Bylund R.   Gustafsson D.   Gyzander E.   Eriksson U.  

Thrombosis Research, Vol. 85, Iss. 2, 1997-01 ,pp. : 133-145

Elsevier

Access to resources Recommend Favorite

IN VITRO STUDIES ON THE EFFECT OF ACTIVATED PROTEIN C ON PLATELET ACTIVATION AND THROMBIN GENERATION

By Kaiser B.   Jeske W.   Hoppensteadt D.H.   Walenga J.M.   Drohan W.   Fareed J.  

Thrombosis Research, Vol. 87, Iss. 2, 1997-07 ,pp. : 197-204

Elsevier

Access to resources Recommend Favorite

Changes of Platelet Surface Antigens in Patients Suffering from Abdominal Septic Shock - An orally active inhibitor op platelet aggregation

By Salat A.   Bodingbauer G.   Boehm D.   Murabito M.   Tochkow E.   Sautner T.   R Mueller M.   Fuegger R.  

Thrombosis Research, Vol. 95, Iss. 6, 1999-09 ,pp. : 289-294

Elsevier

Access to resources Recommend Favorite

Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy

By Li F.   Szabó C.   Pacher P.   Southan G.   Abatan O.   Charniauskaya T.   Stevens M.   Obrosova I.  

Diabetologia, Vol. 47, Iss. 4, 2004-04 ,pp. : 710-717

Springer Publishing Company

Access to resources Recommend Favorite